Synergy of insulin‐like growth factor‐1 and exercise in amyotrophic lateral sclerosis
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of the neuromuscular system resulting in paralysis and ultimately death. Currently, no effective therapy is prescribed for patients; however, several therapeutic strategies are showing promise. Either exercise or treatment with adeno‐associated virus/insulin‐like growth factor–1 alone has therapeutic benefits in an amyotrophic lateral sclerosis transgenic mouse model. We show here that activity duration affects the therapeutic benefit associated with exercise, with 6‐ and 12‐hour exposure to a running wheel providing significant motor function benefits and increased survival. Remarkably, a combination of insulin‐like growth factor–1 gene delivery and exercise has profound effects on survival and function, indicative of synergistic effects with exercise and insulin‐like growth factor–1. Our results indicate that a drug treatment in combination with appropriate exercise may provide the most promising therapy for amyotrophic lateral sclerosis to date. Ann Neurol 2005
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT statement: extension to cluster randomised trials
Campbell, M. K., Elbourne, D. R., & Altman, D. G. (2004) · BMJ · doi:10.1136/bmj.328.7441.702 · Cited by 2,557
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872 · cited 8×
“To evaluate the potential benefits of the various treatments on MN health, we evaluated the lumbar spinal cord at 110 days of age, the time when significant MN death has occurred in nontreated animals.(2) The effects of ER, AAV–IGF-1, and ER AAV– IGF-1 significantly delayed MN death compared with NR animals (see Fig 3…”
BackgroundResultSelf-citationCarro, E., Trejo, J. L., Busiguina, S., & Torres-Aleman, I. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-15-05678.2001 · Cited by 601
Sexual differences in onset of disease and response to exercise in a transgenic model of ALS
Veldink, J. H., Bär, P. R., Joosten, E. A. J., Otten, M., Wokke, J. H. J., & van den Berg, L. H. (2003) · Neuromuscular Disorders · doi:10.1016/s0960-8966(03)00104-4 · Cited by 252
Premorbid weight, body mass, and varsity athletics in ALS
Scarmeas, N., Shih, T., Stern, Y., Ottman, R., & Rowland, L. P. (2002) · Neurology · doi:10.1212/wnl.59.5.773 · Cited by 246
Cited by
ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors
Boillée, S., Vande Velde, C., & Cleveland, D. W. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.018 · Cited by 1,429
Neurogenesis and Exercise: Past and Future Directions
van Praag, H. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8028-z · Cited by 645
Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS
TURNER, B., & TALBOT, K. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.001 · Cited by 496
Behavioral phenotyping strategies for mutant mice
Crawley, J. N. (2008) · Neuron · doi:10.1016/j.neuron.2008.03.001 · Cited by 439
Lost in translation: Treatment trials in the SOD1 mouse and in human ALS
Benatar, M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.015 · Cited by 350
Metadata
- Authors
- Kaspar, B. K., Frost, L. M., Christian, L., Umapathi, P., & Gage, F. H.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2005-04-25
- Volume
- 57
- Issue
- 5
- Pages
- 649-655
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2033046172
- Cited by
- 147
- References
- 5
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.